IN2014DN09618A - - Google Patents

Info

Publication number
IN2014DN09618A
IN2014DN09618A IN9618DEN2014A IN2014DN09618A IN 2014DN09618 A IN2014DN09618 A IN 2014DN09618A IN 9618DEN2014 A IN9618DEN2014 A IN 9618DEN2014A IN 2014DN09618 A IN2014DN09618 A IN 2014DN09618A
Authority
IN
India
Prior art keywords
fusion protein
plasmid
expression
fused
generation
Prior art date
Application number
Other languages
English (en)
Inventor
Dennis J Kopecko
Manuel Osorio
Monica R Foote
Original Assignee
Us Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Sec Dep Of Health And Human Services filed Critical Us Sec Dep Of Health And Human Services
Publication of IN2014DN09618A publication Critical patent/IN2014DN09618A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IN9618DEN2014 2012-05-23 2013-05-22 IN2014DN09618A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650676P 2012-05-23 2012-05-23
PCT/US2013/042240 WO2013177291A1 (en) 2012-05-23 2013-05-22 Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09618A true IN2014DN09618A (enExample) 2015-07-31

Family

ID=48539444

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9618DEN2014 IN2014DN09618A (enExample) 2012-05-23 2013-05-22

Country Status (7)

Country Link
US (1) US9409956B2 (enExample)
EP (1) EP2852405B1 (enExample)
JP (1) JP6216371B2 (enExample)
CN (1) CN104470537B (enExample)
IL (1) IL235615A0 (enExample)
IN (1) IN2014DN09618A (enExample)
WO (1) WO2013177291A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996028551A1 (en) 1995-03-13 1996-09-19 The Secretary Of State For Defence Vaccines for plague
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DK1108034T3 (da) * 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
US20070087013A1 (en) * 2003-12-09 2007-04-19 Donata Sizemore Orally-administered live bacterial vaccines for plague
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof

Also Published As

Publication number Publication date
CN104470537A (zh) 2015-03-25
CN104470537B (zh) 2017-04-26
US20150152144A1 (en) 2015-06-04
EP2852405A1 (en) 2015-04-01
US9409956B2 (en) 2016-08-09
WO2013177291A8 (en) 2014-12-24
IL235615A0 (en) 2015-01-29
EP2852405B1 (en) 2019-03-13
WO2013177291A1 (en) 2013-11-28
JP2015519061A (ja) 2015-07-09
JP6216371B2 (ja) 2017-10-18

Similar Documents

Publication Publication Date Title
MY186535A (en) Novel european prrsv strain
MX2022016002A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2015005797A (es) Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica.
MX350013B (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MX2010001284A (es) Vacunas contra la influenza con multiepitope multimerico.
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
IN2015DN02771A (enExample)
SG10201700916SA (en) Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
NZ703701A (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
IL236663A0 (en) Production of chaperone proteins secreted from the intra-plasmic reticulum (hr chaperones), human, recombinant, natural, by using their natural sequence markers in yeast expression systems
EP3978013A3 (en) A novel live attenuated shigella vaccine
PH12014502004A1 (en) An improved process for preparation of physiologically active polypeptide complex
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
DK201370530A (en) Salmonid alphavirus vaccine
WO2010150242A3 (en) Immunogenic streptococcus pneumoniae peptides and peptide-multimers
MX2015003050A (es) Enjuagues bucales y composiciones de tratamiento de la sensibilidad dental.
NZ589981A (en) Cattle vaccines comprising a disrupted M. bovis bacterium
IN2014DN09618A (enExample)
MX2015014005A (es) Complejo inmunogenico para vacunacion y metodo de obtencion.
MX368484B (es) Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.